APLS - Apellis Pharmaceuticals Inc Stock Price, Fair Value and News

41.44USD-0.56 (-1.33%)Delayed as of 17 May 2024, 12:08 pm ET

Market Summary

USD41.44-0.56

Delayedas of 17 May 2024, 12:08 pm

-1.33%

APLS Alerts

1 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

APLS Stock Price

View Fullscreen

APLS RSI Chart

APLS Valuation

Market Cap

5.1B

Price/Earnings (Trailing)

-12.22

Price/Sales (Trailing)

9.73

EV/EBITDA

-11.86

Price/Free Cashflow

-9.25

APLS Price/Sales (Trailing)

APLS Profitability

EBT Margin

-79.24%

Return on Equity

-156.47%

Return on Assets

-50.16%

Free Cashflow Yield

-10.81%

APLS Fundamentals

APLS Revenue

Revenue (TTM)

524.1M

Rev. Growth (Yr)

284.26%

Rev. Growth (Qtr)

17.73%

APLS Earnings

Earnings (TTM)

-417.3M

Earnings Growth (Yr)

62.64%

Earnings Growth (Qtr)

25.01%

Breaking Down APLS Revenue

52 Week Range

19.8394.75

(Low)(High)

Last 7 days

-1.3%

Last 30 days

-19.0%

Last 90 days

-39.0%

Trailing 12 Months

-53.0%

How does APLS drawdown profile look like?

APLS Financial Health

Current Ratio

3.77

Debt/Equity

0.35

Debt/Cashflow

-5.91

APLS Investor Care

Shares Dilution (1Y)

4.21%

Diluted EPS (TTM)

-3.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	524.1M	0	0	0
2023	105.9M	184.5M	272.9M	396.6M
2022	80.9M	96.6M	113.0M	75.4M
2021	204.6M	158.6M	112.6M	66.6M
2020	6.5M	6.1M	128.4M	250.6M
2019	3.5M	4.0M	4.6M	5.1M
2018	1.6M	0	0	3.0M
2017	0	0	0	277.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Apellis Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	deschatelets pascal	sold	-3,341,850	42.3517	-78,907	chief scientific officer
May 08, 2024	deschatelets pascal	acquired	340,089	4.31	78,907	chief scientific officer
Apr 18, 2024	sullivan timothy eugene	gifted	-	-	14,164	chief financial officer
Apr 18, 2024	sullivan timothy eugene	gifted	-	-	-14,164	chief financial officer
Apr 12, 2024	dunlop a. sinclair	acquired	19,785	13.19	1,500	-
Apr 08, 2024	deschatelets pascal	sold	-3,743,610	54.1711	-69,107	chief scientific officer
Apr 08, 2024	deschatelets pascal	acquired	259,842	3.76	69,107	chief scientific officer
Apr 01, 2024	sullivan timothy eugene	acquired	40,120	10.03	4,000	chief financial officer
Apr 01, 2024	sullivan timothy eugene	sold	-234,640	58.66	-4,000	chief financial officer
Mar 19, 2024	dunlop a. sinclair	sold	-1,068,160	57.179	-18,681	-

Which funds bought or sold APLS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	sold off	-100	-493,246	-	-%
May 15, 2024	Boxer Capital, LLC	unchanged	-	-1,864,080	101,454,000	5.01%
May 15, 2024	ORBIMED ADVISORS LLC	added	40.73	21,081,800	76,284,700	1.40%
May 15, 2024	WYNNEFIELD CAPITAL INC	unchanged	-	-10,800	587,800	0.23%
May 15, 2024	JANUS HENDERSON GROUP PLC	reduced	-7.85	-217,747	2,052,340	-%
May 15, 2024	SOROS FUND MANAGEMENT LLC	new	-	525,963	525,963	0.01%
May 15, 2024	Granahan Investment Management, LLC	added	57.66	1,386,030	3,914,570	0.14%
May 15, 2024	EVENTIDE ASSET MANAGEMENT, LLC	unchanged	-	-226,578	12,331,700	0.19%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-648	35,268	-%
May 15, 2024	ALGERT GLOBAL LLC	added	27.00	605,000	3,055,000	0.12%

Are Funds Buying or Selling APLS?

Are funds buying APLS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APLS

No. of Funds

Unveiling Apellis Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	5.3%	6,303,584	SC 13G
Feb 14, 2024	ecor1 capital, llc	9.4%	11,173,068	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.9%	13,411,111	SC 13G/A
Feb 13, 2024	vanguard group inc	8.06%	9,555,678	SC 13G/A
Feb 08, 2024	wellington management group llp	13.91%	16,477,850	SC 13G/A
Sep 08, 2023	wellington management group llp	12.55%	14,770,859	SC 13G/A
Jul 18, 2023	ecor1 capital, llc	5.4%	6,307,547	SC 13G
Jul 07, 2023	blackrock inc.	4.9%	5,747,184	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	5.3%	5,842,660	SC 13G
Feb 14, 2023	avoro capital advisors llc	9.6%	10,625,000	SC 13G/A

Recent SEC filings of Apellis Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 09, 2024	4	Insider Trading
May 08, 2024	144	Notice of Insider Sale Intent
May 07, 2024	10-Q	Quarterly Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 19, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading

Peers (Alternatives to Apellis Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Apellis Pharmaceuticals Inc News

Latest updates

Apellis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	17.7%	172,325,000	146,377,000	110,399,000	94,969,000	44,846,000	22,663,000	22,056,000	16,322,000	14,381,000	60,290,000	5,650,000	623,000	723,500	824,000	924,500	1,025,000	2,275,000	1,478,779	1,342,000	1,421,000	867,000
Operating Expenses	1.5%	234,415,000	230,894,500	247,479,000	215,410,000	219,929,000	186,716,000	174,994,000	164,946,000	143,379,000	149,694,000	133,645,000	194,910,000	124,591,000	119,879,000	130,198,000	115,508,000	-	-	69,948,000	-	-
S&GA Expenses	-100.0%	-	141,701,000	145,648,000	111,373,000	102,093,000	84,367,500	78,406,000	63,203,000	51,187,000	41,462,000	45,763,000	48,967,000	40,579,000	44,492,000	36,991,000	28,414,000	29,504,000	27,468,000	18,629,000	12,778,000	8,171,000
R&D Expenses	22.3%	84,701,000	69,281,500	79,421,000	95,658,000	110,027,000	99,423,000	95,207,000	101,661,000	90,945,000	78,181,000	87,733,000	95,943,000	84,012,000	50,337,500	93,207,000	87,094,000	69,282,000	78,472,000	51,319,000	50,698,000	40,480,000
EBITDA Margin	40.5%	-0.78	-1.31	-2.21	-3.54	-6.48	-8.55	-5.53	-6.50	-8.55	-11.03	-2.94	-2.05	-	-	-	-	-	-	-	-	-
Interest Expenses	-	1,643,000	-	1,643,000	-	1,643,000	-	1,643,000	-	3,360,000	-	3,372,000	-	6,893,000	-	9,100,000	-	3,829,000	28,000	231,000	140,000	588,000
Income Taxes	-85.9%	200,000	1,414,000	233,000	194,000	300,000	-1,471,000	446,000	486,000	1,208,000	352,000	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	24.0%	-66,253,000	-87,153,000	-140,004,000	-121,843,000	-177,496,000	-167,462,000	-190,823,000	-155,491,000	-137,727,000	-147,581,000	-195,571,000	-219,191,000	-183,659,000	-	-	-	-	-	-	-	-
EBT Margin	40.3%	-0.79	-1.33	-2.22	-3.56	-6.53	-8.64	-5.59	-6.58	-8.65	-11.21	-3.05	-2.16	-	-	-	-	-	-	-	-	-
Net Income	25.0%	-66,423,000	-88,576,000	-140,237,000	-122,037,000	-177,778,000	-165,991,000	-191,269,000	-155,977,000	-138,935,000	-147,933,000	-195,571,000	-219,191,000	-183,659,000	78,265,000	-135,700,000	-118,617,000	-168,822,000	-113,218,000	-69,825,000	-71,090,000	-50,574,000
Net Income Margin	40.3%	-0.80	-1.33	-2.22	-3.56	-6.53	-8.65	-5.61	-6.61	-8.67	-11.21	-4.62	-2.90	-	-	-	-	-	-	-	-	-
Free Cashflow	-36.0%	-133,276,000	-97,970,000	-169,132,000	-150,527,000	-177,879,000	-141,595,000	-154,613,000	-107,415,000	-111,646,000	-112,518,000	-168,977,000	-128,936,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	5.5%	832	789	818	916	979	760	873	1,002	1,146	882	526	700	810	961	768	870	689	389	466	317	318
Current Assets	5.9%	811	766	797	893	954	720	832	960	1,104	824	475	655	774	917	742	854	672	373	451	308	311
Cash Equivalents	-6.9%	327	351	452	616	765	552	584	604	633	640	284	271	265	567	416	317	418	352	434	289	288
Inventory	10.2%	161	146	99.00	103	85.00	86.00	60.00	48.00	33.00	16.00	2.00	4.00	-	-	-	-	-	-	-	-	-
Net PPE	-3.5%	4.00	4.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00	7.00	7.00	2.00	2.00	2.00	2.00	1.00	1.00
Liabilities	-4.9%	565	594	586	570	567	590	565	668	684	683	583	841	758	756	662	638	430	355	327	158	94.00
Current Liabilities	-13.0%	215	248	186	175	139	168	115	127	125	132	94.00	158	84.00	128	75.00	58.00	51.00	66.00	45.00	36.00	20.00
Long Term Debt	0.1%	93.00	93.00	93.00	93.00	93.00	93.00	93.00	189	189	189	190	386	386	359	354	349	145	143	-	-	-
LT Debt, Non Current	-100.0%	-	93.00	93.00	93.00	93.00	93.00	93.00	189	189	189	190	386	386	359	354	349	145	143	-	-	-
Shareholder's Equity	37.1%	267	195	232	345	412	170	307	334	462	199	-	-	52.00	205	106	232	259	34.00	140	159	225
Retained Earnings	-2.2%	-2,900	-2,837	-2,748	-2,600	-2,486	-2,308	-2,142	-1,951	-1,795	-1,656	-1,508	-1,313	-1,093	-926	-1,004	-868	-750	-581	-468	-398	-327
Additional Paid-In Capital	4.6%	3,174	3,036	2,982	2,955	2,900	2,480	2,453	2,289	2,260	1,857	1,453	1,174	1,147	1,131	1,112	1,101	1,008	616	608	558	552
Shares Outstanding	1.4%	121	120	118	118	116	111	110	107	106	84.00	87.00	81.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	10,700	-	-	-	4,800	-	-	-	4,074	-	-	-	1,954	-	-	-	1,151	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-35.9%	-132,983	-97,875	-169,085	-150,155	-177,620	-140,744	-154,417	-107,024	-111,560	-112,499	-168,625	-128,688	-153,314	141,979	-99,824	-94,294	-108,349	-82,071	-53,597	-39,907	-35,560
Share Based Compensation	15.8%	30,349	26,219	21,625	29,278	28,823	24,241	23,541	22,530	20,773	19,312	17,194	17,722	16,439	12,494	12,099	11,489	9,294	7,107	5,295	4,183	4,559
Cashflow From Investing	-7425.0%	-293	4.00	-47.00	-372	-259	124,129	124,784	82,929	-271,949	84,980	179,649	129,752	-146,765	-91.00	198,763	-287,807	-227,854	-155	-471	-192	-875
Cashflow From Financing	2865.4%	108,212	-3,913	5,746	1,560	391,106	-15,946	9,636	-4,735	376,704	383,958	2,120	4,526	1,632	6,317	926	281,668	403,267	209	198,950	40,964	148,418

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APLS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 172,325	$ 44,846
Operating expenses:
Cost of sales	20,209	7,809
Research and development	84,701	110,027
Selling, general and administrative	129,505	102,093
Total operating expenses:	234,415	219,929
Net operating loss	(62,090)	(175,083)
Interest income	3,303	5,393
Interest expense	(6,967)	(7,529)
Other (expense)/ income, net	(499)	(277)
Net loss before taxes	(66,253)	(177,496)
Income tax expense	170	282
Net loss	(66,423)	(177,778)
Other comprehensive gain/(loss):
Foreign currency translation	17	100
Total other comprehensive income	17	100
Comprehensive loss, net of tax	$ (66,406)	$ (177,678)
Net loss per common share, basic	$ (0.54)	$ (1.56)
Net loss per common share, diluted	$ (0.54)	$ (1.56)
Weighted-average number of common shares used in net loss per common share, basic	122,957	113,872
Weighted-average number of common shares used in net loss per common share, diluted	122,957	113,872
Product revenue, net [Member]
Revenue:
Total revenue	$ 163,075	$ 38,800
Licensing and other revenue [Member]
Revenue:
Total revenue	$ 9,250	$ 6,046

APLS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 325,923	$ 351,185
Accounts receivable, net	267,837	206,442
Inventory	161,283	146,362
Prepaid assets	43,163	38,820
Restricted cash	1,103	1,114
Other current assets	12,119	22,408
Total current assets	811,428	766,331
Non-current assets:
Right-of-use assets	14,994	16,745
Property and equipment, net	4,195	4,345
Other assets	1,313	1,309
Total assets	831,930	788,730
Current liabilities:
Accounts payable	26,788	37,516
Accrued expenses	101,399	127,806
Current portion of development liability	77,287	75,830
Current portion of lease liabilities	6,257	6,441
Deferred Revenue	3,560
Total current liabilities	215,291	247,593
Long-term liabilities:
Long-term development liability	244,426	239,817
Convertible senior notes	93,109	93,033
Lease liabilities	9,770	11,454
Other liabilities	2,658	2,312
Total liabilities	565,254	594,209
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized, and zero shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 200,000 shares authorized at March 31, 2024 and December 31, 2023; 121,267 shares issued and outstanding at March 31, 2024, and 119,556 shares issued and outstanding at December 31, 2023	12	12
Additional paid-in capital	3,174,100	3,035,539
Accumulated other comprehensive loss	(3,525)	(3,542)
Accumulated deficit	(2,903,911)	(2,837,488)
Total stockholders' equity	266,676	194,521
Total liabilities and stockholders' equity	$ 831,930	$ 788,730

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

CEO	Dr. Cedric Francois M.D., Ph.D.
WEBSITE	apellis.com
INDUSTRY	Biotechnology
EMPLOYEES	767

Apellis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Apellis Pharmaceuticals Inc? What does APLS stand for in stocks?

APLS is the stock ticker symbol of Apellis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Apellis Pharmaceuticals Inc (APLS)?

As of Thu May 16 2024, market cap of Apellis Pharmaceuticals Inc is 5.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLS stock?

You can check APLS's fair value in chart for subscribers.

What is the fair value of APLS stock?

You can check APLS's fair value in chart for subscribers. The fair value of Apellis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Apellis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Apellis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether APLS is over valued or under valued. Whether Apellis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Apellis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLS.

What is Apellis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, APLS's PE ratio (Price to Earnings) is -12.22 and Price to Sales (PS) ratio is 9.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLS PE ratio will change depending on the future growth rate expectations of investors.